JPRN-UMIN000006403已完成未知
A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer. - A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •central nervous system metastasis other active double cancer inadequately controlled diabetes, heart disease, renal disease or liver disfunction. severe peritoneal metastasis, interstitial pneumonia or pulmonary fibrosis previous history of angina or myocardinal infarction severe drug hypersensitivity bleeding tendency
研究者
相似试验
已完成
2 期
Phase II study of trastuzumab and paclitaxel in patients with HER2 positive (IHC 3+, IHC 2+ and FISH +) previously treated advanced or recurrent gastric cancerHER2 positive advanced or recurrent gastric cancerJPRN-UMIN000006223Japanese Foundation for Multidisciplinary Treatment of Cancer35
已完成
1 期
Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.HER2-positive gastric cancerJPRN-UMIN000014873Kyoto Prefectural University of Medicine, Gatroenterology and Hepatology23
已完成
1 期
Phase I/II study of Paclitaxel+Trastuzumab therapy in 2nd line treatment for advanced or recurrent gastric cancer with HER2 positive.HER2-positive gastric cancerJPRN-UMIN000011863Osaka Medical College Hospital100
招募中
1 期
Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive.advanced or recurrent HER2-positive gastric cancerJPRN-UMIN000008623The Cancer Institute Hospital of JFCR36
招募中
2 期
Phase II trial of trastumab and weekly paclitaxel for breast cancer. -Japan Breast Cancer Research Network (JBCRN) TrialMetastatic breast cancerJPRN-UMIN000004819Japan Breast Cancer Research Network (JBCRN)25